Coaptation assist device for repairing cardiac valves and associated systems and methods are disclosed herein. A coaptation assist device configured in accordance with embodiments of the present technology can include, for example, a fixation member configured to press against cardiac tissue proximate to a native valve annulus, and a stationary coaptation structure extending away from the fixation member. The coaptation structure can include an anterior surface configured to coapt with a first native leaflet during systole and a posterior surface configured to displace at least a portion of a second native leaflet. The device also includes at least one sensor configured to detect parameters associated with at least one of cardiac function and device functionality. The sensors can be pressure sensors configured to detect left atrial pressure and/or left ventricular pressure.

An acoustic sensor is configured to provide accurate and robust measurement of bodily sounds under a variety of conditions, such as in noisy environments or in situations in which stress, strain, or movement may be imparted onto a sensor with respect to a patient. Embodiments of the sensor provide a conformable electrical shielding, as well as improved acoustic and mechanical coupling between the sensor and the measurement site.

An acoustic sensor is configured to provide accurate and robust measurement of bodily sounds under a variety of conditions, such as in noisy environments or in situations in which stress, strain, or movement may be imparted onto a sensor with respect to a patient. Embodiments of the sensor provide a conformable electrical shielding, as well as improved acoustic and mechanical coupling between the sensor and the measurement site.

A method of performing impedance measurements on a subject. The method includes using a processing system to determine at least one impedance measurement to be performed, and at one electrode arrangement associated with the determined measurement. A representation of the arrangement is displayed so the impedance measurement can be performed once the electrodes have been arranged in accordance with the displayed representation.

A method of performing impedance measurements on a subject. The method includes using a processing system to determine at least one impedance measurement to be performed, and at one electrode arrangement associated with the determined measurement. A representation of the arrangement is displayed so the impedance measurement can be performed once the electrodes have been arranged in accordance with the displayed representation.

The systems, devices, and methods presented herein use a blood pump to obtain measurements of cardiac function. The system can quantify the functioning of the native heart by measuring certain parameters/signals such as aortic pressure or motor current, then calculate and display one or more cardiac parameters and heart function parameters, such as left ventricular pressure, left ventricular end diastolic pressure, or cardiac power output. These parameters provide valuable information to a user regarding current cardiac function, as well as positioning and function of the blood pump. In some embodiments, the system can act as a diagnostic and therapeutic tool. Providing cardiac parameters in real-time, along with warnings about adverse effects and recommendations to support cardiac function, such as increasing or decreasing the volumetric flow rate of blood pumped by the device, administering pharmaceutical therapies, and/or repositioning the blood pump allow clinicians to better support and treat cardiovascular disease.

The systems, devices, and methods presented herein use a blood pump to obtain measurements of cardiac function. The system can quantify the functioning of the native heart by measuring certain parameters/signals such as aortic pressure or motor current, then calculate and display one or more cardiac parameters and heart function parameters, such as left ventricular pressure, left ventricular end diastolic pressure, or cardiac power output. These parameters provide valuable information to a user regarding current cardiac function, as well as positioning and function of the blood pump. In some embodiments, the system can act as a diagnostic and therapeutic tool. Providing cardiac parameters in real-time, along with warnings about adverse effects and recommendations to support cardiac function, such as increasing or decreasing the volumetric flow rate of blood pumped by the device, administering pharmaceutical therapies, and/or repositioning the blood pump allow clinicians to better support and treat cardiovascular disease.

A continuous and self-calibration method and system for monitoring oxygen saturation of a patient are provided. An example system includes a wearable device having a first optical sensor to measure a first red wavelength photoplethysmography (PPG) signal and a first infrared wavelength PPG signal and a second optical sensor to measure a second red wavelength PPG signal and a second infrared wavelength PPG signal. The system further includes a processor configured to repeatedly determine that conditions for recalibration of the first optical sensor are satisfied, determine a first ratio for obtaining the oxygen saturation, a first parameter for modifying the first red wavelength PPG signal, a second parameter for modifying the first infrared wavelength PPG signal, and a second ration for obtaining the oxygen saturation. The processor is further configured to determine a value of the oxygen saturation and provide a message regarding a health status of the patient.

The present application provides for use of a somatosensory evoked potential (SEP) during the hyperacute stroke phase as marker for predicting the outcome of endovascular treatment in a patient suffering from acute ischemic stroke, wherein when the SEP ipsilateral to the stroke site has an amplitude from 60% to 100% with respect to the corresponding SEP contralateral to the stroke site this is indicative of good outcome of the endovascular treatment, whereas when the SEP ipsilateral to the stroke site has an amplitude from 0% to 20% with respect to the corresponding SEP contralateral to the stroke site this is indicative of bad outcome of the endovascular treatment.

The present application provides for use of a somatosensory evoked potential (SEP) during the hyperacute stroke phase as marker for predicting the outcome of endovascular treatment in a patient suffering from acute ischemic stroke, wherein when the SEP ipsilateral to the stroke site has an amplitude from 60% to 100% with respect to the corresponding SEP contralateral to the stroke site this is indicative of good outcome of the endovascular treatment, whereas when the SEP ipsilateral to the stroke site has an amplitude from 0% to 20% with respect to the corresponding SEP contralateral to the stroke site this is indicative of bad outcome of the endovascular treatment.